EXACT Sciences Co. (NASDAQ:EXAS) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 12,219,909 shares, an increase of 26.1% from the January 12th total of 9,688,211 shares. Based on an average daily volume of 4,257,669 shares, the days-to-cover ratio is presently 2.9 days. Approximately 10.4% of the shares of the company are sold short.
A number of research firms have recently commented on EXAS. BidaskClub raised shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Leerink Swann set a $67.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a research report on Friday. Benchmark reaffirmed a “buy” rating and set a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Goldman Sachs Group started coverage on shares of EXACT Sciences in a research report on Monday, January 29th. They set a “neutral” rating and a $51.00 target price on the stock. Finally, Bank of America boosted their target price on shares of EXACT Sciences from $56.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. EXACT Sciences currently has an average rating of “Buy” and a consensus target price of $52.84.
EXACT Sciences (NASDAQ:EXAS) traded up $1.34 on Friday, reaching $45.90. 2,981,107 shares of the company’s stock were exchanged, compared to its average volume of 3,475,568. EXACT Sciences has a 1 year low of $18.30 and a 1 year high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. The firm has a market capitalization of $5,320.00, a P/E ratio of -39.91 and a beta of 0.58.
A number of institutional investors and hedge funds have recently bought and sold shares of EXAS. New York State Common Retirement Fund boosted its stake in EXACT Sciences by 8.9% during the second quarter. New York State Common Retirement Fund now owns 156,741 shares of the medical research company’s stock worth $5,544,000 after buying an additional 12,821 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of EXACT Sciences in the 2nd quarter valued at $217,000. FMR LLC boosted its stake in shares of EXACT Sciences by 32.7% in the 2nd quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after purchasing an additional 571,796 shares in the last quarter. California Public Employees Retirement System boosted its stake in shares of EXACT Sciences by 5.9% in the 2nd quarter. California Public Employees Retirement System now owns 185,100 shares of the medical research company’s stock valued at $6,547,000 after purchasing an additional 10,300 shares in the last quarter. Finally, Advisor Group Inc. boosted its stake in shares of EXACT Sciences by 0.8% in the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 82.32% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/09/exact-sciences-co-exas-short-interest-up-26-1-in-january.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.